drugset / Trial / NCT05776979
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
NaSingle-groupOpen-labelTreatment
Summary
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
Timeline
- Start
- 2023-08-17
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isatuximab | Monoclonal antibody | — | Intravenous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |